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Abstract
Background: Clinical evidence is important for improving the treatment of patients by health care providers. In
the study of cardiovascular diseases, large-scale clinical trials involving thousands of participants are required to
evaluate the risks of cardiac events and/or death. The problems encountered in conducting the Japanese Acute
Myocardial Infarction Prospective (JAMP) study highlighted the difficulties involved in obtaining the financial and
infrastructural resources necessary for conducting large-scale clinical trials. The objectives of the current study were:
1) to clarify the current funding and infrastructural environment surrounding large-scale clinical trials in
cardiovascular and metabolic diseases in Japan, and 2) to find ways to improve the environment surrounding
clinical trials in Japan more generally.
Methods: We examined clinical trials examining cardiovascular diseases that evaluated true endpoints and
involved 300 or more participants using Pub-Med, Ichushi (by the Japan Medical Abstracts Society, a non-profit
organization), websites of related medical societies, the University Hospital Medical Information Network (UMIN)
Clinical Trials Registry, and clinicaltrials.gov at three points in time: 30 November, 2004, 25 February, 2007 and 25
July, 2009.
Results: We found a total of 152 trials that met our criteria for ‘large-scale clinical trials’ examining cardiovascular
diseases in Japan. Of these, 72.4% were randomized controlled trials (RCTs). Of 152 trials, 9.2% of the trials
examined more than 10,000 participants, and 42.8% examined between 1,000 and 10,000 participants. The number
of large-scale clinical trials markedly increased from 2001 to 2004, but suddenly decreased in 2007, then began to
increase again. Ischemic heart disease (39.5%) was the most common target disease. Most of the larger-scale trials
were funded by private organizations such as pharmaceutical companies. The designs and results of 13 trials were
not disclosed.
Conclusions: To improve the quality of clinical trials, all sponsors should register trials and disclose the funding
sources before the enrolment of participants, and publish their results after the completion of each study.
Background
Large numbers of clinical and non-clinical investigations
are required to obtain evidence to improve the treat-
ment of patients. This evidence can benefit the medical
practice of health care providers by informing treatment
guidelines and providing the rationale on which to make
treatment decisions.
Clinical trials are necessary for producing appropriate
clinical evidence. In clinical trials examining cardiovas-
cular diseases, large-scale clinical trials with thousands
of participants are often required to evaluate the risks of
cardiac events and/or death, because it is necessary to
evaluate the incidence of cardiovascular events that are
relatively uncommon. Such clinical trials provide evi-
dence about the most appropriate treatment regimen for
preventing cardiovascular and metabolic diseases.
In the 1970s, researchers began to conduct clinical
trials in Western countries, with the incidence of cardio-
vascular events as an endpoint [1,2]. Although the large-
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10 years ago, the number of large-scale clinical trials has
increased. Recently, a large number of clinical trials
evaluating the incidence of cardiac events and/or death
using hard endpoints have been conducted in the field
of cardiovascular and metabolic medicine.
The Japanese Acute Myocardial Infarction Prospective
(JAMP) study was the first non-pharmaceutical com-
pany-supported multicenter trial of a medication in
Japan, and the results have already been reported [3].
Briefly, this randomized parallel-group study was carried
out across 48 institutions from 1993 to 2000. The pri-
mary endpoint of the study was a composite of cardiac
events involving at least one of the following: cardiac or
non-cardiac death, recurrent non-fatal myocardial
infarction, coronary revascularization, and hospitaliza-
tion because of worsening angina or congestive heart
failure. In total, 888 of 1,163 participants with acute
myocardial infarction (AMI) were eligible for the full
analysis set (FAS). Patients were randomly assigned to
two groups; 422 received angiotensin-converting enzyme
(ACE) inhibitors and 466 did not receive ACE inhibi-
tors. The mean follow-up period was 5.8 years. The
JAMP study group concluded that no significant
improvement in outcome was associated with ACE inhi-
bitor administration in subjects who survived AMI in a
Japanese study population.
Following the JAMP study, we conducted a review to
highlight important issues regarding large-scale clinical
trials. The major issues revealed by our review were the
funding sources and infrastructure surrounding clinical
trials. Financial and infrastructural resources must be
maintained for clinical trials to be conducted appropri-
ately. However, a high investigation cost is required for
this, and obtaining adequate funding is critical for con-
ducting clinical trials. The infrastructural environment
necessary for clinical trials is currently inadequate,
although the situation is improving, with efforts being
made by government, medical institutions and other
organizations. At present, Japanese clinical trials are
typically funded by various sources, including public
agencies, private companies and foundations. However,
some researchers have suggested that industry-funded
studies are likely to be affected by biases in their results
and interpretations [4-10]. For example, Ridker, et al.
reported that cardiovascular trials funded by for-profit
organizations reported between 2000 and 2005, were
more likely to report positive findings than those funded
by not-for-profit organizations [4]. Given the current
research situation in the medical and pharmaceutical
industries, it is not possible to completely avoid conflicts
of interests among researchers. Recently, the Interna-
tional Committee of Medical Journal Editors (ICMJE)
requested that sponsors disclose certain information
regarding trial management, including funding sources
[11]. However, there are currently no comprehensive
regulations for managing conflicts of interest.
The current study had two main objectives:
1) To clarify the current funding and infrastructural
environment surrounding large-scale clinical trials in
cardiovascular and metabolic diseases in Japan
2) To find more general ways to improve the environ-
ment surrounding clinical trials in Japan.
Methods
Our search covered all large-scale clinical trials whose
primary endpoints were true endpoints in clinical trials
examining cardiovascular and metabolic diseases. A true
endpoint was defined as an endpoint consisting of cardio-
vascular events, such as myocardial infarction, chronic
heart failure, ischemic heart attack, and/or death. We
defined ‘large-scale clinical trials’ as trials where the tar-
get number of participants or enrolled number of partici-
pants was 300 or more. If a trial was discontinued before
enrolling 300 participants, but the planned number of
participants was 300 or more, this trial was also regarded
as ‘large-scale clinical trial’. We searched for clinical trials
using PubMed, Ichushi (Japana Centra Revuo Medicina
by the Japan Medical Abstracts Society, a non-profit
organization), URL: http://login.jamas.or.jp/), websites of
related medical societies, University Hospital Medical
Information Network (UMIN) Clinical Trials Registry
(URL: http://www.umin.ac.jp/ctr/index-j.htm), and clini-
caltrials.gov (URL: http://www.clinicaltrials.gov/).
We conducted searches at three different times. The
first search was carried out in 2004, with a cut-off date
of 30 November, 2004. The second and third searches
were conducted in 2007 and 2009, with cut-off dates on
25 February, 2007 and on 25 July, 2009, respectively.
The second search was conducted to evaluate the
changes in the environment surrounding clinical trials
in Japan after improving the awareness of conflicts of
interest in 2005-2006. The third search was conducted
to evaluate the impacts of some scandals regarding clini-
cal researches that were reported by the media in Japan
in 2007-2008.
For all clinical trials that met the criteria described
above, we recorded the 1) sponsor, 2) objectives of trial,
3) design (randomized clinical trial or non-randomized
clinical trial), 4) interventions, 5) chief investigator, 6)
contact address, 7) starting year of the trial, 8) duration
of the trial/ending year of the trial, 9) number of enrolled
participants or target number of participants, 10) results
of trial, 11) publications of results or methods of trial, 12)
funding agencies, and 13) others. Here, we defined a
‘sponsor’ as ‘an individual, company, institution or orga-
nization that took responsibility for the initiation, man-
agement and/or financing of a clinical trial’ [12-14].
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1) Screening of large-scale clinical trials in cardiovascular
diseases
We found a total 152 trials conducted in Japan that met
our criteria for ‘large-scale clinical trials’ examining car-
diovascular diseases. Sixty-four trials were found in the
search conducted on 30 November, 2004, 53 additional
trials were found on 25 February, 2007, and 35 addi-
tional trials were found on 25 July, 2009.
2) Trial design (RCT/non-RCT) and number of participants
We categorized the trials as randomized controlled trials
(RCTs) or non-randomized controlled trials (non-RCTs)
a c c o r d i n gt ot h e i rd e s i g n ,a ss h o w ni nT a b l e1 .7 2 . 4 %
(110/152) of the trials were RCTs, and 27.6% (42/152)
were non-RCTs. Examining the numbers of participants
revealed that 9.2% (14/152) of the trials examined more
than 10,000 participants, 42.8% (65/152) examined
between 1,000 and 10,000 participants, and 42.8% (65/
152) examined less than 1,000 participants. 28.6% (4/14)
of the trials with 10,000 participants or more were
RCTs, 70.8% (46/65) of the trials with 1,000 to 10,000
participants, and 81.5% (53/65) of the trials with less
than 1,000 participants were RCTs. This result indicated
that the proportion of RCTs tended to be higher in
trials with a lower number of participants.
3) Number of trials by starting year
We counted the number of trials according to the start-
ing year and trial design (Figure 1). From 1992, several
large-scale clinical trials were started each year. After
2001, the number of large-scale clinical trials markedly
increased to more than 10 per year. In 2004, the num-
ber of large-scale clinical trials peaked, with 16 trials
started within a year. In 2007, the number suddenly
decreased to only seven, then increased again after 2007.
4) Number of trials by target disease
We categorized the numbers of trials by target disease
(Table 2). Large-scale clinical trials examining ischemic
heart disease (39.5%) were conducted most frequently,
followed by studies of hypertension (22.4%), cerebrovascu-
lar disorders (18.4%), and heart failure (11.2%). No clear
trend was observed between target disease and trial design.
5) Number of trials by funding sources
We analyzed the relationships among starting year of
the trials, their numbers of participants and the types of
funding agencies (Figure 2). ‘Public’ funding agencies
include governmental organizations such as the Ministry
of Health, Labour and Welfare, and ‘Private’ agencies
include non-governmental or civilian organizations such
as pharmaceutical companies.
Most of the larger-scale studies were funded by pri-
vate organizations. The number of public funded studies
increased from the latter half of the 1990s. Trials with
combined funding sources were conducted until 2005,
but no combined funding trials were conducted after
2006. We consistently found that the majority of large-
scale clinical trials were privately funded. In particular,
most large studies (10,000 or more participants) were
privately funded.
Summary statistics of the numbers of participants by
funding source are shown in Table 3. The median num-
ber of participants in publicly funded trials was 762,
that in privately funded trials was 1,000, and that in
trials with combined funding sources or other sources
was 2,100.
6) Number of trials by presence or absence of publication
We searched for publications arising from each trial in
medical journals (including abstracts of medical or
scientific congresses). Overall, 60.5% (92/152) of the
trials were published (Table 4). Of the published trials,
70 of 92 were RCTs and 22 were non-RCTs. 39.5% (60/
152) of the trials were not published. Of these 60 trials,
39 trials were RCTs and 21 were non-RCTs. However,
trial designs and/or results in 33 out of 39 RCTs and 14
out of 21 non-RCTs were found in clinical trial regis-
tries, such as clinicaltrials.gov and the UMIN Clinical
Trials Registry. Six RCTs and seven non-RCTs were not
disclosed anywhere.
Table 1 Numbers of trials by number of participants and trial design (RCT or non-RCT)
Number of participants Number of trials Proportion of RCT (RCT/Total)
RCT* Non-RCT* Total
≥10,000 4 10 14 (9.2%) 0.286
1,000-10,000 46 19 65 (42.8%) 0.708
<1,000 53 12 65 (42.8%) 0.815
Unknown
† 7 1 8 (5.3%) -
Total 110 42 152 (100%) 0.724
* RCT: randomized controlled trial, Non-RCT: non-randomized controlled trial
† Eight multi-national trials where the number of Japanese participants was not known were categorized as ‘unknown’.
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We found a total of 152 trials that met our criteria for
‘large-scale clinical trials’ examining cardiovascular dis-
eases in Japan. Sixty-four trials were found on 30
November, 2004, 53 trials were additionally found on 25
February, 2007, and 35 additional trials were found on
25 July, 2009.
72.4% (110/152) of the trials were RCTs, and 27.6%
(42/152) were non-RCTs. Only 14 (9.2%) trials were
large-scale cardiovascular clinical trials involving 10,000
or more participants, while there were 65 trials (42.8%)
with less than 1,000 participants. Thus, larger clinical
trials in Japan were found to be relatively rare. We pro-
pose two possible causes for this finding: first, it may be
perceived that conducting such large clinical trials is not
necessary for events that are considered to have a high
incidence of mortality and morbidity. Second, limited
funding and human resources may limit the feasibility of
large-scale clinical trials.
In trials with larger sample sizes, the proportion of
non-RCTs was higher than among trials with smaller
sample sizes. This finding is in accord with our proposal
that large-scale clinical trials may be restricted because
of limited funding and human resources.
We compared trial designs and the number of partici-
pants by search date (Table 5). This analysis revealed that
the proportion of trials of cardiovascular diseases in Japan
with smaller sample sizes increased over time. Further-
more, the ratio of RCTs to non-RCTs was greater among
the small-scale trials than among the large-scale trials.
After 2001, the number of large-scale clinical trials
markedly increased to more than 10. In 2004, the num-
ber of large-scale clinical trials peaked, with 16 trials
started within a year. In 2007, the number suddenly
decreased to seven per year, then increased again after
2007. This pattern may be related to changes in the cli-
mate of public opinion regarding financial disclosures
revealing relationships between study sponsors and
funding agencies. Some reports in the mass media in
Japan regarding private industry funding to academic
sponsors without advance disclosures in 2007 and 2008
might have affected this tendency.
Ischemic heart disease (39.5%) was the most common
target disease for large-scale clinical trials in Japan, fol-
lowed by hypertension (22.4%), cerebrovascular disor-
ders (18.4%), and heart failure (11.2%). Large-scale
clinical trials were conducted for not only lifestyle-
related chronic diseases but also for acute diseases such
as myocardial infarction.
Our evaluation of changes in target diseases is shown
in Table 6. The number of trials targeting ischemic
heart disease gradually decreased over the study period,
although it remained the major target disease in 2009.
The numbers of trials targeting hypertension and cere-
brovascular disorders decreased over the study period.
On the other hand, the number of trials focusing on
chronic kidney disease markedly increased after 2007.
This was not a target disease in any trials before 2007,
but seven trials on chronic kidney disease were started
after 2007. This may reflect a heightened awareness of
chronic kidney disease as a major risk factor for cardio-
vascular events [15].
We analyzed the relationship among the starting year
of trials, the number of participants and the types of
funding agencies. ‘Public’ funding agencies included gov-
ernmental organizations such as the Ministry of Health,
Labour and Welfare, and ‘Private’ funding agencies
included non-governmental or civilian organizations
such as pharmaceutical companies.
Most of the larger-scale trials were funded by private
organizations, such as pharmaceutical companies. Sev-
eral publicly funded trials were started in 1998, but few
publicly funded trials were conducted after 2005. Trials
with combined funding sources were conducted until
2005, but no such trials were started after 2006. The
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Figure 1 Number of trials by starting year and trial design
(RCT or non-RCT). RCT: randomized controlled trial, Non-RCT: non-
randomized controlled trial. Ten clinical trials (six RCTs and four non-
RCTs) whose starting years were unknown were not counted.
Table 2 Numbers of trials by target disease and trial
design (RCT or non-RCT)
Target disease Number of trials
Total RCT* Non-RCT*
Ischemic heart disease 60 (39.5%) 39 21
Hypertension 34 (22.4%) 21 13
Cerebrovascular disorder 28 (18.4%) 23 5
Heart failure 17 (11.2%) 12 5
Hyperlipidemia 13 (8.6%) 9 4
Diabetes mellitus 10 (6.6%) 9 1
Chronic kidney disease 7 (4.6%) 5 2
Arrhythmia 5 (3.3%) 5 0
Total 152 (100%) 108 46
* RCT: randomized controlled trial, Non-RCT: non-randomized controlled trial
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privately-funded. In particular, most studies with 10,000
or more participants were privately funded.
The median number of participants in public funded
trials was 762, that in private funded trials was 1,000,
and that in trials with combined funding sources or
o t h e rs o u r c e sw a s2 , 1 0 0 .T h i sr e s u l ts u g g e s t st h a ti ti s
possible to conduct larger scale clinical trials with pri-
vate funding, but that it may be difficult to conduct stu-
dies of this size with funding from public sources. This
trend was similar to the global trends for 2000-2005,
where the median sample sizes of clinical trials funded
by not-for-profit organizations and by for-profit organi-
zations were 421 and 1486, respectively [4].
Thirteen trials (six RCTs and seven non-RCTs) did
not disclose their designs or results at all. When we
examined the changes in numbers of ‘unpublished trials’
in Table 7, the number did not decline between 2004
and 2009, resembling the global situation in which 54%
of the trials were unpublished [16]. Among 12 com-
pleted trials with more than 10,000 participants, of
which five were industry funded, 10 trials (83.3%) had
been published. On the other hand, 37 (72.5%) of 51
completed trials with less than 1,000 participants had
been published. When we counted the numbers of
‘unpublished’ trials by the type of funder, seven trials
100
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Figure 2 Dot plot of starting year, funding agency, and number of participants.
Table 3 Summary statistics about numbers of
participants by funding source
Parameter Number of trials
Public Private Combined Total
Number of trials (N) * 20 95 29 144
Mean 1,257 3,948 5,062 3,799
Standard deviation 1,340 7,959 12,064 8,463
Median 762 1,000 2,100 1,007
Max 5,000 53,000 65,434 65,434
* Eight multi-national trials where the numbers of Japanese participants was
not known were excluded.
Table 4 Number of trials by presence or absence of
publication in medical journals
Publication status Number of trials (N = 152)
RCT* Non-RCT* Total
Published trials 70 22 92 (60.5%)
Unpublished trials 39 21 60 (39.5%)
Completed but unpublished trials 14 8 22
Ongoing unpublished trials 25 13 38
* RCT: randomized controlled trial, Non-RCT: non-randomized controlled trial
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means we may require different approaches to improve
the current problems. For example, improving the
awareness of the importance of publishing results would
be effective for the sponsors of self-funded trials, while
issuing guidelines to force disclosure would be appropri-
ate for the industry-funded trials. Japan established a
clinical trial registry system in 2005 [17]. Three systems,
i.e. UMIN Clinical Trials Registry; Japan Pharmaceutical
Information Center (JAPIC); and Japan Medical Associa-
tion, Center for Clinical Trials (JMACCT) were incorpo-
rated into the Japan Primary Registries Network in 2008.
As mentioned by the ICMJE in 2004 [18], the Declara-
tion of Helsinki revised in 2008 [19] and the CONSORT
declaration in 2010 [20], the disclosure of trial protocol
summaries and results is important to avoid publication
bias. Therefore, the situation in Japan is currently
problematic.
Conclusions
To minimize the bias caused by funding sources,
entirely publicly funded trials should be conducted by
‘neutral’ investigators. However, this is difficult because
of limitations in the financial resources necessary for
conducting large-scale clinical trials in Japan. This
appears to be why most of the trials revealed by our
search were funded by private industry.
Some sponsors required more than one funding source.
This finding indicates that some sponsors were con-
cerned with obtaining sufficient funding for large-scale
clinical trials. However, in some large-scale trials, the
relationships between sponsor and funding agencies were
not clear. Some sponsors did not disclose information
about trials, although this publication policy may have
changed. We propose that all sponsors of clinical trials
should register trials and disclose their funding sources
before the enrolment of participants, and publish their
results after the completion of each study to improve the
quality of clinical trials. For this purpose, improving the
sponsors’ awareness of the importance of publications
and issuing guidelines to mandate the disclosure of fund-
ing sources can offer the solutions to these problems.
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